Search Results

You are looking at 1 - 10 of 93 items :

  • "cyclic citrullinated peptide" x
Clear All

Clin Chem Lab Med 2010;48(2):225–230 2010 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2010.046 2010/428 Article in press - uncorrected proof Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis Sang Mee Hwang, Jeong-Ok Kim, Young-Mi Yoo, Sue Shin, Jin Q Kim, Myoung Hee Park and Eun Young Song* Department of Laboratory Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea Abstract Background: Anti-cyclic citrullinated peptide

diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155–63. 11. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32:197–204. 12. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47:1089–93. 13. Jansen AL, van der Horst-Bruinsma I, van

Clin Chem Lab Med 2009;47(7):842–847 2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.189 2007/25 Article in press - uncorrected proof Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection Iman H. Bassyouni1, Yasser Ezzat2, Sherif Hamdy3 and Roba M. Talaat4,* 1 Department of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Egypt 2 Department of Rheumatology and Rehabilitation, Faculty of Medicine, Fayoum University, Egypt 3

Clin Chem Lab Med 2009;47(12):1525–1530 2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.288 2009/263 Article in press - uncorrected proof Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis Andrea Tesija Kuna1,a,*, Lovro Lamot2,a, Marijana Miler1, Miroslav Harjacek2, Ana-Maria Simundic1 and Nada Vrkic1 1 University Department of Chemistry, ‘‘Sestre Milosrdnice’’ University Hospital, Zagreb, Croatia 2 Division of Clinical Immunology and Rheumatology, Children’s Hospital

and anti-keratin antibodies [2, 3]. It is now known that these antibodies all contain citrulline residues and are called anti-cyclic citrullinated peptide (aCCP) [4]. The presence of aCCP antibodies is strongly associated with a more severe, destructive disease course [5] and counts as one of the classification criteria in the diagnosis of RA [6]. Interestingly, aCCP can be detected years before onset of the disease [5, 7, 8]. Assays detecting antibodies against aCCP are more specific and have similar sensitivity compared to RF. Recently, a new test for the

Introduction The detection of anti-citrullinated protein antibodies in blood is mainly used for the diagnosis of rheumatoid arthritis. In this group of antibodies, anti-cyclic citrullinated peptide (CCP) IgG antibody is currently the most frequently used parameter in daily practice. It is considered to be a highly specific diagnostic marker for rheumatoid arthritis [ 1 ], [ 2 ], [ 3 ]. Because of the high positive predictive value for this disease, this test was also included in the 2010 ACR/EULAR classification criteria for rheumatoid arthritis [ 4 ]. Recently

–6]. Therefore, several new autoantibodies have been reported in patients with RA, and their clinical value has been evaluated. Most, such as antiperinuclear factor antibodies (APF), antikeratin antibodies, anti-RA33 and anti-Sa, cannot demonstrate to have adequate sensitivity and specificity to form a basis for clinical and therapeutic decisions [7–11]. An early attempt to create an ideal RA marker was the anti-cyclic citrullinated peptide antibody, first described by Schellekens et al. [12]. Thus the anti-CCP antibody assay has generated great interest for a long time. The

peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis – a prospective cohort study. Arthritis Rheum 2004; 50:709–15. 11. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32:231–8. 12. Keitel W, Genth E, Gromnica-Ihle E, Häntzschel H, Kalden JR, Mathies H, et al. Leitlinie für das Symptom Gelenkschwellung – Primärärztliches Problemmanagement und Überweisungsindikationen. Z

recombinant rat filaggrin by enzyme-linked immunosorbent assay. A highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2002 ; 46 : 2051 –8. 41. Nogueira L, Foussadier A, Vincent C. VIDAS-EDRA fully automated testing of autoantibodies to citrullinated proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2004 ; 6 : S5 . 42. Bizzaro N, Pasini P, Mazzanti G, Villalta D, Tonutti E, Tozzoli R. Combined use of the anti-filaggrin and anti-cyclic citrullinated peptide antibody assays for the diagnosis of rheumatoid arthritis

-Oleas, Servicio de Inmunologı́a, Edificio de Laboratorios, 3a planta, Hospital Universitario Virgen del Rocı́o, Avenida Manuel Siurot s/n, 41013, Sevilla, Spain Phone: q34-955013231, Fax: q34-955013221, E-mail: Keywords: anti-cyclic citrullinated peptide antibodies (anti-CCP); rheumatoid arthritis; rheumatoid factor; third-generation anti-CCP ELISA. Introduction Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of peripheral joints, leading to severe destruction. This disease affects between 0.5% and 1% of